search
Back to results

Efficacy of the Photobiomodulation on the Pelvi-perineal Pain in Immediate Post-partum Situation

Primary Purpose

Pelvic Pain

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
MILTA Device
" control 1 " fake MILTA device
Sponsored by
Elsan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Pelvic Pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Woman aged 18 years or older
  • Primi or multiparous patient
  • Natural childbirth, regardless of the method of extraction (spontaneous, vacuum, forceps), and damage to the perineum (simple tear, episiotomy, obstetric anal sphincter injury)
  • Patients affiliated to a health insurance plan
  • Agreeing to participate in the study and having signed an informed consent

Exclusion Criteria:

  • Immediate complications related to the childbirth and requiring management in the continuing care unit (delivery haemorrhage, eclampsia, etc.)
  • Severe neonatal complications requiring reanimation.
  • Patient with a cardiac pacemaker
  • Presence of a disease and/or taking photo-sensitising treatment
  • Patient under legal protection

Sites / Locations

  • Clinique la ChataigneraieRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

No Intervention

Arm Label

" control 1 " fake MILTA device

MILTA Device

" control 2 " standard pain management with medication

Arm Description

Fake device (control 1) which emits 10% red light (and no infrared) so that the difference between the two machines cannot be seen with the naked eye. The magnets present in the real device are absent in the fake machine and replaced by inert materials of the same mass.

The MILTA device used for the study is composed of a panel which gathers 18 emitters composed of red, green and blue LEDs, 3 nanopulsed infrared laser diodes (cold laser), 3 infrared diodes and a permanent magnet

In first intention: PARACETAMOL: max 1 g x 4 / 24 h Second intention: IBUPROFEN: max 100 mg x 2 for 48 h Third intention: ACUPAN 20 mg in sugar 3 times per 24 h Last intention: ACTISKENAN 10 mg x 4 / 24 h

Outcomes

Primary Outcome Measures

Evaluation of the effectiveness of photobiomodulation (PBM) on pain in immediate postpartum patients
Evaluated the superiority of the experimental group (MILTA device) to control 1 (fake device) using a Visual Analog Scale (VAS) collected before and after pain management (1st session of PBM)
Evaluation of the effectiveness of photobiomodulation on pain in immediate postpartum patients
Evaluated the non-inferiority with of the experimental group (MILTA device) to control 2 (standard of care) using a Visual Analog Scale (VAS) collected before and after pain management

Secondary Outcome Measures

Evaluation of the effectiveness of photobiomodulation on pain after the second PBM session
Evaluated the superiority of the experimental group (MILTA device) to control 1 (fake device) using a Visual Analog Scale (VAS) collected before and after pain management (2nd session of PBM)
Characterisation of pain
Pain will be characterised using the shortened QDSA questionnaire. The control groups will be compared with the MILTA device.
Characterisation of pain
Pain will be characterised using the shortened QDSA questionnaire. The control groups will be compared with the MILTA device.
Evaluation of the total quantity of analgesics consumed during the hospital stay
Recording of the type and dose of analgesics consumed.
Evaluation of the improvement of postpartum comfort
Postpartum confort will be assessed using 5 modalities scale
Evaluation of the improvement of postpartum comfort
Postpartum confort will be assessed using 5 modalities scale
Evaluation of the involvement of caregivers during the hospital stay
Recording the number of calls to the healthcare team related to pain
Safety evaluation
Adverse event record

Full Information

First Posted
April 29, 2021
Last Updated
February 13, 2023
Sponsor
Elsan
search

1. Study Identification

Unique Protocol Identification Number
NCT04896034
Brief Title
Efficacy of the Photobiomodulation on the Pelvi-perineal Pain in Immediate Post-partum Situation
Official Title
Evaluation of the Efficacy of the Photobiomodulation on the Pelvi-perineal Pain in Patients in Immediate Post-partum Situation
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 6, 2021 (Actual)
Primary Completion Date
September 6, 2023 (Anticipated)
Study Completion Date
October 6, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Elsan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Photobiomodulation (PBM), evaluated in this study, will be delivered by a CE marked class IIa medical device (MILTA technology), composed of a panel that gathers 18 emitters. This is an innovative, alternative, soft technology, based on a cross action of LED light emission, a low intensity nanopulsed laser and a magnetic tunnel. The sessions last 10 minutes each, in total in the study two sessions will be delivered.
Detailed Description
In a woman's life, maternity is an important stage that is not without consequences, not only in daily life but also in future life. Perineal pain syndrome is a problem frequently encountered in the postpartum period and the review of the literature shows that 95 to 100% of women who have given birth by the vaginal way and who present perineal lesions, suffer from perineal pain at 24 hours of the delivery and approximately 60% of them remain painful at 7 days of the delivery. This incidence can decrease to 42% and 11% respectively in the absence of perineal lesions. Pain in the postpartum period can not only limit a woman's mobility and affect her quality of life, but can also interfere with the care of her child and thus with the establishment of a good mother-child relationship, and thus prevent her from fulfilling her new role as a mother. Finally, acute pain that is not treated can become chronic and affect long-term physical and psychological health. Pain management in the immediate postpartum period currently involves the use of level 1 analgesics (paracetamol, NSAIDs), the effectiveness of which is uncertain, and level 2 analgesics (weak morphine derivatives, Acupan, Tramadol), which are more effective for pain, but are sometimes badly tolerated or contraindicated in the case of breastfeeding. Recently, several publications tend to show that alternative solutions would allow a more satisfactory approach to the management of painful patients. In this study, the investigators propose to evaluate the benefit of an innovative analgesic treatment in the immediate postpartum period using photobiomodulation (PBM) by evaluating pain using a Visual Analog Scale. PBM, discovered in the 1950s, uses the properties of light. The PBM corresponds to all the non-thermal and non-cytotoxic biological effects caused by the exposure of tissues to light sources in the visible and near-infrared range. More precisely, certain wavelengths of the light spectrum (red-infrared) lead to a cascade of biological effects within the cell: reduction of pain, regulation of inflammation and acceleration of the healing process. The objective of this study is to analyze the possibility of replacing chemical medication by a non-invasive, painless technology in patients who have just given birth. This technology is already used for anti-inflammatory and analgesic actions in indications such as stomatology, rheumatology, post-operation and traumatology. This is part of the field of NMIs (non-medicinal interventions).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pelvic Pain

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single-center, adaptive, prospective, three-arm randomized, controlled, double-blind study for 2 arms. 3 groups will be constituted, according to a 1:3:3 ratio: 1 group " control 1 " with 2 sessions of PBM ( fake device). 1 experimental group with 2 sessions of PBM (real device) 1 group " control 2 " with standard pain management (i.e. medication).
Masking
ParticipantInvestigator
Masking Description
The experimental group (real device) and the control 1 group ( fake device) will be in double-blind, neither the investigator nor the patient will know the allocated group.
Allocation
Randomized
Enrollment
677 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
" control 1 " fake MILTA device
Arm Type
Placebo Comparator
Arm Description
Fake device (control 1) which emits 10% red light (and no infrared) so that the difference between the two machines cannot be seen with the naked eye. The magnets present in the real device are absent in the fake machine and replaced by inert materials of the same mass.
Arm Title
MILTA Device
Arm Type
Experimental
Arm Description
The MILTA device used for the study is composed of a panel which gathers 18 emitters composed of red, green and blue LEDs, 3 nanopulsed infrared laser diodes (cold laser), 3 infrared diodes and a permanent magnet
Arm Title
" control 2 " standard pain management with medication
Arm Type
No Intervention
Arm Description
In first intention: PARACETAMOL: max 1 g x 4 / 24 h Second intention: IBUPROFEN: max 100 mg x 2 for 48 h Third intention: ACUPAN 20 mg in sugar 3 times per 24 h Last intention: ACTISKENAN 10 mg x 4 / 24 h
Intervention Type
Device
Intervention Name(s)
MILTA Device
Intervention Description
Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
Intervention Type
Device
Intervention Name(s)
" control 1 " fake MILTA device
Intervention Description
Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
Primary Outcome Measure Information:
Title
Evaluation of the effectiveness of photobiomodulation (PBM) on pain in immediate postpartum patients
Description
Evaluated the superiority of the experimental group (MILTA device) to control 1 (fake device) using a Visual Analog Scale (VAS) collected before and after pain management (1st session of PBM)
Time Frame
30 minutes after first PBM session for the experimental and control 1 groups
Title
Evaluation of the effectiveness of photobiomodulation on pain in immediate postpartum patients
Description
Evaluated the non-inferiority with of the experimental group (MILTA device) to control 2 (standard of care) using a Visual Analog Scale (VAS) collected before and after pain management
Time Frame
30 minutes after first PBM session for the experimental group or 30 minutes after analgesic treatment for the group control 2
Secondary Outcome Measure Information:
Title
Evaluation of the effectiveness of photobiomodulation on pain after the second PBM session
Description
Evaluated the superiority of the experimental group (MILTA device) to control 1 (fake device) using a Visual Analog Scale (VAS) collected before and after pain management (2nd session of PBM)
Time Frame
30 minutes after second PBM session for the experimental and control 1 groups
Title
Characterisation of pain
Description
Pain will be characterised using the shortened QDSA questionnaire. The control groups will be compared with the MILTA device.
Time Frame
30 minutes after first PBM session for the experimental and control 1 groups and 30 minutes after analgesic treatment for the group control 2
Title
Characterisation of pain
Description
Pain will be characterised using the shortened QDSA questionnaire. The control groups will be compared with the MILTA device.
Time Frame
30 minutes after second PBM session for the experimental and control 1 groups and 30 minutes after analgesic treatment for the group control 2 (Day 1)
Title
Evaluation of the total quantity of analgesics consumed during the hospital stay
Description
Recording of the type and dose of analgesics consumed.
Time Frame
through the hospital stay, an average of 2 or 3 days
Title
Evaluation of the improvement of postpartum comfort
Description
Postpartum confort will be assessed using 5 modalities scale
Time Frame
30 minutes after first PBM session for the experimental and control 1 groups and 30 minutes after analgesic treatment for the group control 2
Title
Evaluation of the improvement of postpartum comfort
Description
Postpartum confort will be assessed using 5 modalities scale
Time Frame
30 minutes after second PBM session for the experimental and control 1 groups and 30 minutes after analgesic treatment for the group control 2 (Day 1)
Title
Evaluation of the involvement of caregivers during the hospital stay
Description
Recording the number of calls to the healthcare team related to pain
Time Frame
through the hospital stay, an average of 2 or 3 days
Title
Safety evaluation
Description
Adverse event record
Time Frame
through study completion, an average of 10 days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Woman aged 18 years or older Primi or multiparous patient Natural childbirth, regardless of the method of extraction (spontaneous, vacuum, forceps), and damage to the perineum (simple tear, episiotomy, obstetric anal sphincter injury) Patients affiliated to a health insurance plan Agreeing to participate in the study and having signed an informed consent Exclusion Criteria: Immediate complications related to the childbirth and requiring management in the continuing care unit (delivery haemorrhage, eclampsia, etc.) Severe neonatal complications requiring reanimation. Patient with a cardiac pacemaker Presence of a disease and/or taking photo-sensitising treatment Patient under legal protection
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marie-Claude ANTON, MD
Phone
(0)473408082
Ext
+33
Email
sec.dr.mc.ab@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-Claude ANTON, MD
Organizational Affiliation
Clinique la Chataigneraie
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinique la Chataigneraie
City
Beaumont
ZIP/Postal Code
63110
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie-Claude ANTON, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24346253
Citation
Persico G, Vergani P, Cestaro C, Grandolfo M, Nespoli A. Assessment of postpartum perineal pain after vaginal delivery: prevalence, severity and determinants. A prospective observational study. Minerva Ginecol. 2013 Dec;65(6):669-78.
Results Reference
background
Citation
Morin C, Leymarie MC. La douleur périnéale en post-partum: revue de la littérature. La Revue Sage-femme (2013) 12; 263-268
Results Reference
background
PubMed Identifier
30770967
Citation
Manresa M, Pereda A, Bataller E, Terre-Rull C, Ismail KM, Webb SS. Incidence of perineal pain and dyspareunia following spontaneous vaginal birth: a systematic review and meta-analysis. Int Urogynecol J. 2019 Jun;30(6):853-868. doi: 10.1007/s00192-019-03894-0. Epub 2019 Feb 15.
Results Reference
background
PubMed Identifier
15507941
Citation
Macarthur AJ, Macarthur C. Incidence, severity, and determinants of perineal pain after vaginal delivery: a prospective cohort study. Am J Obstet Gynecol. 2004 Oct;191(4):1199-204. doi: 10.1016/j.ajog.2004.02.064.
Results Reference
background
PubMed Identifier
25555717
Citation
Turmo M, Echevarria M, Rubio P, Almeida C. Development of chronic pain after episiotomy. Rev Esp Anestesiol Reanim. 2015 Oct;62(8):436-42. doi: 10.1016/j.redar.2014.10.008. Epub 2014 Dec 30. English, Spanish.
Results Reference
background
Citation
HAS. Douleur chronique: reconnaître le syndrome douloureux chronique, l'évaluer et orienter le patient. Consensus formalisé - December 2008
Results Reference
background
PubMed Identifier
2050168
Citation
Skovlund E, Fyllingen G, Landre H, Nesheim BI. Comparison of postpartum pain treatments using a sequential trial design. I. Paracetamol versus placebo. Eur J Clin Pharmacol. 1991;40(4):343-7. doi: 10.1007/BF00265841.
Results Reference
background
PubMed Identifier
1443811
Citation
Behotas S, Chauvin A, Castiel J, Martin A, Boureau F, Barrat J, Lienhart A. [Analgesic effect of ibuprofen in pain after episiotomy]. Ann Fr Anesth Reanim. 1992;11(1):22-6. doi: 10.1016/s0750-7658(05)80316-8. French.
Results Reference
background
Citation
Gabelle C, Cassa S, Bouvard M, Knoepffler F. Intérêts des anti-inflammatoires non stéroïdes dans les douleurs périnéales du post-partum. J Gyneco. Obst. Biol. Reprod (2004) 33(1): 67 (10)
Results Reference
background
Citation
Wehrle M. Prise en charge de la douleur post-épisiotomie en suites de couches: Analyse des pratiques professionnelles à la Maternité Régionale Universitaire de Nancy. Mémoire Université de Lorraine (2015) hal-02110831.
Results Reference
background
PubMed Identifier
26455776
Citation
Battut A, Nizard J. [Impact of pelvic floor muscle training on prevention of perineal pain and dyspareunia in postpartum]. Prog Urol. 2016 Mar;26(4):237-44. doi: 10.1016/j.purol.2015.09.006. Epub 2015 Oct 9. French.
Results Reference
background
Citation
Golka M. Haute fréquence et douleur périnéale du post-partum. Mémoire Université d'Aix Marseille (2017) dumas-01646228
Results Reference
background
Citation
Boureau F, Luu M. Méthodes d'évaluation de la douleur. Douleur et Analgésie (1988) 6; 1(2): 65-78.
Results Reference
background
PubMed Identifier
28748217
Citation
Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-361. doi: 10.3934/biophy.2017.3.337. Epub 2017 May 19.
Results Reference
background
Citation
Moreira Rocha Jr A. Et al. Effects of Low-Level Laser Therapy on the progress of wound healing in humans: the contribution of in vitro and in vivo experimental studies. J. Vas. Bras 2007; 6(3): 258-266
Results Reference
background
PubMed Identifier
22714676
Citation
Luo L, Sun Z, Zhang L, Li X, Dong Y, Liu TC. Effects of low-level laser therapy on ROS homeostasis and expression of IGF-1 and TGF-beta1 in skeletal muscle during the repair process. Lasers Med Sci. 2013 May;28(3):725-34. doi: 10.1007/s10103-012-1133-0. Epub 2012 Jun 20.
Results Reference
background
PubMed Identifier
23832179
Citation
Cidral-Filho FJ, Mazzardo-Martins L, Martins DF, Santos AR. Light-emitting diode therapy induces analgesia in a mouse model of postoperative pain through activation of peripheral opioid receptors and the L-arginine/nitric oxide pathway. Lasers Med Sci. 2014 Mar;29(2):695-702. doi: 10.1007/s10103-013-1385-3. Epub 2013 Jul 6.
Results Reference
background
PubMed Identifier
15345176
Citation
Enwemeka CS, Parker JC, Dowdy DS, Harkness EE, Sanford LE, Woodruff LD. The efficacy of low-power lasers in tissue repair and pain control: a meta-analysis study. Photomed Laser Surg. 2004 Aug;22(4):323-9. doi: 10.1089/pho.2004.22.323.
Results Reference
background
Citation
Ahangar FA et Al. Efficace of nano-pulsed magneto infrared Laser Therapy with a fixed dose combination tablet of oral Ibuprofen and paracetamol on the reduction of endodontie pain: a clinical study. Contemporary Med. Res. (2017); 4(8): 1782-1787
Results Reference
background
PubMed Identifier
19913903
Citation
Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. Lancet. 2009 Dec 5;374(9705):1897-908. doi: 10.1016/S0140-6736(09)61522-1. Epub 2009 Nov 13. Erratum In: Lancet. 2010 Mar 13;375(9718):894.
Results Reference
background
PubMed Identifier
31360374
Citation
Ezzati K, Fekrazad R, Raoufi Z. The Effects of Photobiomodulation Therapy on Post-Surgical Pain. J Lasers Med Sci. 2019 Spring;10(2):79-85. doi: 10.15171/jlms.2019.13. Epub 2019 Feb 25.
Results Reference
background
Citation
FDA, Multiple Endpoints in Clinical Trials Guidance for Industry, January 2017
Results Reference
background

Learn more about this trial

Efficacy of the Photobiomodulation on the Pelvi-perineal Pain in Immediate Post-partum Situation

We'll reach out to this number within 24 hrs